Initial Treatment of Uncomplicated Hypertension

Guideline-Based First-Line Recommendations

The European Society of Cardiology recommends ACE inhibitors, ARBs, dihydropyridine calcium channel blockers, and thiazide/thiazide-like diuretics as first-line BP-lowering medications for hypertension management, with beta-blockers reserved for patients with specific compelling indications 1, 2
The American Diabetes Association recommends ACE inhibitors, ARBs, thiazide-like diuretics, or dihydropyridine calcium channel blockers as the drug classes demonstrated to reduce cardiovascular events in patients with diabetes and hypertension 3
Beta-blockers should only be combined with other major BP-lowering drug classes when there are compelling indications, including angina, post-myocardial infarction, heart failure with reduced ejection fraction (HFrEF), or for heart rate control 1, 2

Beta-blockers are less effective in BP reduction compared to other drug classes, particularly in resistant hypertension where beta-blockers are less potent than spironolactone 1
The ARB losartan was more effective than the beta-blocker atenolol in reducing cardiovascular events, particularly stroke, in hypertensive patients with left ventricular hypertrophy 4

Bisoprolol has clear evidence-based indications in specific clinical scenarios, including post-acute coronary syndrome, where short-acting beta-1 selective beta-blockers should be initiated within 24 hours if no contraindications exist 7
Bisoprolol demonstrated a 32% reduction in all-cause mortality in the CIBIS-II trial, with sudden deaths reduced by 44%, in patients with heart failure with reduced ejection fraction 5
Bisoprolol should be used in patients with compelling cardiac indications, including angina, recent MI, HFrEF, or requiring heart rate control 1, 2

For a patient with newly diagnosed uncomplicated hypertension, start with telmisartan 40-80 mg once daily as monotherapy if BP is 140-159/90-99 mmHg 1
If BP ≥160/100 mmHg, initiate combination therapy immediately with telmisartan plus either a calcium channel blocker or thiazide diuretic, preferably as a single-pill combination 1, 3
Reserve bisoprolol for patients with recent myocardial infarction, heart failure with reduced ejection fraction, angina requiring rate control, or atrial fibrillation requiring rate control 5, 7

Never combine two RAS blockers due to lack of benefit and increased adverse events, including hyperkalemia, syncope, and acute kidney injury 1, 3
In pregnancy-related hypertension, neither telmisartan nor bisoprolol is first-line; labetalol, methyldopa, or nifedipine are preferred, though bisoprolol is considered safe in European countries where labetalol is unavailable 8
For patients with COPD, beta-1 selective agents like bisoprolol are safer than non-selective beta-blockers if a beta-blocker is truly needed, but ARBs like telmisartan avoid bronchospasm risk entirely 8